First published: 25th October 2023

Cumulus Neuroscience presented data at the Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting on Wednesday October 25th in Boston, Massachusetts.

Cumulus presented three (3) poster presentations, two featuring internally generated data collected from Cumulus-sponsored studies partnering with academic and clinical institutions, and one featuring data generated from a study sponsored by INmune Bio Inc. (Nasdaq: INMB) a clinical stage biopharma company.

The poster featuring data generated from a Phase Ib study in Alzheimer’s Disease (AD) sponsored by INmune Bio titled, “Feasibility of the Cumulus electrophysiological neurocognitive platform to enable de-centralized trials in Alzheimer's Disease,” demonstrated that the Cumulus Neuroassessment platform can be frequently and accurately used by patients living with mild to moderate AD in the home over long periods of time (e.g., >3 months) including ‘burst’ measurement periods in-lab or at-home where each cognitive assessment is administered several times in relatively quick succession. The study was carried out during the pandemic, and demonstrated how the system could be used autonomously at-home even by substantially impaired patients, avoiding the need for in-person assessment visits.

These findings are consistent with data presented in a second poster titled, “A real-world, longitudinal observational study in patients with Alzheimer’s Disease dementia and healthy controls, using frequent repeated digital measurements performed at-home on the Cumulus Platform: a preliminary report” which features data from CNS-101, a real-world feasibility study being conducted in collaboration with the Universities of Oxford and Cambridge. Importantly, preliminary analysis of the burst stage indicates these types of digital technologies have construct validity, distinguishing groups, correlating with conventional benchmarks, across behavioral and biosignal endpoints.

A third poster titled, “Validating a novel digital cognitive platform: sensitivity to change following an alcohol challenge,” featured data from a study focused on validating a new cognitive assessment battery including tasks targeting four cognitive functions affected early in the AD continuum:

• Double-Take, an N-back working memory test
• Memory Match, a paired episodic memory test
• Rapid Response, a simple reaction time test
• Symbol Swap, a symbol coding task (DSST)

This study demonstrated that these novel digital cognitive tests can sensitively measure change in dementia-relevant cognitive functions over the timescale of acute alcohol intoxication and return to sobriety. Importantly, it was possible for study participants to repeat the tests multiple times with minimal practice effects, suggesting that this cognitive assessment battery can be scaled up to support clinical trials, utilizing burst measurement to reduce within-subject error and trial size.

“Subtle changes in cognition can be difficult to measure in dementia clinical trials using existing tools,” said Brian Murphy, PhD, Founder and Chief Scientific Officer of Cumulus. “Collectively, these data sets confirm that it is feasible for patients living with mild to moderate Alzheimer’s dementia to use the Cumulus Platform to provide objective, frequent and patient-centered tracking of functional neurophysiology that is reflective of their cognitive function in their day-to-day life. We are excited about the potential to dramatically accelerate Alzheimer’s clinical studies by capturing longitudinal electrophysiological correlates characteristic of Alzheimer’s Disease pathology in de-centralized trials. We are grateful to all the study participants and our research collaborators.”

AD is a progressive disease that affects brain function, memory, and other cognitive abilities. It is the most common cause of dementia, affecting millions of people worldwide. Symptoms usually develop slowly and worsen over time, including memory loss, confusion, difficulty with language and communication, mood swings, and changes in behavior and personality. Currently, there is no known cure for AD.